Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: a randomized, double‐blind, placebo‐controlled study
The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
Aims: To compare the efficacy, safety and tolerability of linagliptin or placebo administered for 24 weeks in combination with pioglitazone in patients with type 2 diabetes mellitus (T2DM) exhibiting insufficient glycaemic control (HbA1c 7.5–11.0%). Methods: Patients were randomized to receive the initial combination of 30 mg pioglitazone plus 5 mg linagliptin (n = 259) or pioglitazone plus placebo (n = 130), all once daily. The primary endpoint was change from baseline in HbA1c after 24 weeks of treatment, adjusted for baseline HbA1c and prior antidiabetes medication. Results: After 24 weeks of treatment, the adjusted mean change (±s.e.) in HbA1c with the initial combination of linagliptin plus pioglitazone was −1.06% (±0.06), compared with −0.56% (±0.09) for placebo plus pioglitazone. The difference in adjusted mean HbA1c in the linagliptin group compared with placebo was −0.51% (95% confidence interval [CI] −0.71, −0.30; p < 0.0001). Reductions in fasting plasma glucose (FPG) were significantly greater for linagliptin plus pioglitazone than with placebo plus pioglitazone; −1.8 and −1.0 mmol/l, respectively, equating to a treatment difference of −0.8 mmol/l (95% CI −1.2, −0.4; p < 0.0001). Patients taking linagliptin plus pioglitazone, compared with those receiving placebo plus pioglitazone, were more likely to achieve HbA1c of <7.0% (42.9 vs. 30.5%, respectively; p = 0.0051) and reduction in HbA1c of ≥0.5% (75.0 vs. 50.8%, respectively; p < 0.0001). β ‐cell function, exemplified by the ratio of relative change in adjusted mean HOMA‐IR and disposition index, improved. The proportion of patients that experienced at least one adverse event was similar for both groups. Hypoglycaemic episodes (all mild) occurred in 1.2% of the linagliptin plus pioglitazone patients and none in the placebo plus pioglitazone group. Conclusion: Initial combination therapy with linagliptin plus pioglitazone was well tolerated and produced significant and clinically meaningful improvements in glycaemic control. This combination may offer a valuable additive initial treatment option for T2DM, particularly where metformin either is not well tolerated or is contraindicated, such as in patients with renal impairment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
β-Cell Deficit and Increased β-Cell Apoptosis in Humans With Type 2 Diabetes
Butler, A. E., Janson, J., Bonner-Weir, S., Ritzel, R., Rizza, R. A., & Butler, P. C. (2003) · Diabetes · doi:10.2337/diabetes.52.1.102 · Cited by 4,011
Oral antihyperglycemic therapy for type 2 diabetes mellitus
Cheng, A. Y. Y. (2005) · Canadian Medical Association Journal · doi:10.1503/cmaj.1031414 · Cited by 502 · cited 1×
“Hypoglycaemia as a side effect of diabetes treatment is a major concern and some OADs, such as the insulin secretagogues, may be associated with an increase in the occurrence of hypoglycaemic events [26].”
BackgroundDel Prato, S., Barnett, A. H., Huisman, H., Neubacher, D., Woerle, H. ‐., & Dugi, K. A. (2011) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01350.x · Cited by 299
Self-citationTaskinen, M. ‐., Rosenstock, J., Tamminen, I., Kubiak, R., Patel, S., Dugi, K. A., & Woerle, H. ‐. (2011) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01326.x · Cited by 294
Self-citationThomas, L., Eckhardt, M., Langkopf, E., Tadayyon, M., Himmelsbach, F., & Mark, M. (2008) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.135723 · Cited by 283 · cited 3×
“Linagliptin (5 mg once daily) is a novel DPP-4 inhibitor, with a unique xanthine-based structure [5].”
BackgroundInfluentialGarber, A. J., Schweizer, A., Baron, M. A., Rochotte, E., & Dejager, S. (2007) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2006.00684.x · Cited by 268 · cited 1×
“However, previous findings suggest that when used in combination, DPP-4 inhibitors may elicit small increases in the weight gain induced by pioglitazone [22,23,25].”
Rosenstock, J., Kim, S. W., Baron, M. A., Camisasca, R. ‐., Cressier, F., Couturier, A., & Dejager, S. (2007) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2006.00698.x · Cited by 255 · cited 2×
“although the insulin sensitizing effects of pioglitazone could complicate assessing the effect of linagliptin, as also appears to have been the case in other trials assessing DPP-4 inhibitors in combination with gliptins [22,23].”
ResultThe Metabolism and Disposition of the Oral Dipeptidyl Peptidase-4 Inhibitor, Linagliptin, in Humans
Blech, S., Ludwig-Schwellinger, E., Gräfe-Mody, E. U., Withopf, B., & Wagner, K. (2010) · Drug Metabolism and Disposition · doi:10.1124/dmd.109.031476 · Cited by 189 · cited 3×
“In contrast, linagliptin is excreted via the enterohepatic system with ∼85% excreted unchanged in the faeces [9].”
BackgroundHeise, T., Graefe‐Mody, E. U., Hüttner, S., Ring, A., Trommeshauser, D., & Dugi, K. A. (2009) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01046.x · Cited by 175 · cited 1×
“The tolerability of linagliptin in this study was consistent with the previously reported safety profile of the drug [6,7] and no new safety concerns emerged.”
ResultSelf-citationHüttner, S., Graefe-Mody, E. U., Withopf, B., Ring, A., & Dugi, K. A. (2008) · The Journal of Clinical Pharmacology · doi:10.1177/0091270008323753 · Cited by 139 · cited 2×
“The tolerability of linagliptin in this study was consistent with the previously reported safety profile of the drug [6,7] and no new safety concerns emerged.”
BackgroundResultSelf-citationGraefe-Mody, E. U., Padula, S. J., Ring, A., Withopf, B., & Dugi, K. A. (2009) · Current Medical Research and Opinion · doi:10.1185/03007990903094361 · Cited by 63 · cited 1×
“Therefore, linagliptin co-administration is not associated with clinically relevant effects on the pharmacokinetics or pharmacodynamics of other drugs commonly prescribed to patients with T2DM, such as metformin [12], pioglitazone [13], glyburide [14], simvastatin [15], warfarin [16], digoxin [17] or oral contraceptiv…”
BackgroundSelf-citationYoon, K., Shockey, G., Teng, R., Golm, G. T., Thakkar, P., Meehan, A. G., Williams‐Herman, D., Kaufman, K. D., Amatruda, J. M., & Steinberg, H. O. (2011) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2010.02589.x · Cited by 53 · cited 2×
“although the insulin sensitizing effects of pioglitazone could complicate assessing the effect of linagliptin, as also appears to have been the case in other trials assessing DPP-4 inhibitors in combination with gliptins [22,23].”
ResultOverview of the Gliptin Class (Dipeptidyl Peptidase-4 Inhibitors) in Clinical Practice
Bohannon, N. J. V. (2009) · Postgraduate Medicine · doi:10.3810/pgm.2009.01.1953 · Cited by 49 · cited 1×
“DPP-4 inhibitors generally are associated with an inherently low risk of hypoglycaemia [27] and, in this study, hypoglycaemia was rare when linagliptin was added to pioglitazone.”
BackgroundRetlich, S., Withopf, B., Greischel, A., Staab, A., Jaehde, U., & Fuchs, H. (2009) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.676 · Cited by 49
Mikhail, N. E. (2008) · Vascular Health and Risk Management · doi:10.2147/vhrm.s3374 · Cited by 40 · cited 1×
“It is known that prolonged treatment with thiazolidinediones can cause weight gain [24] and, in this study, a small increase (1.”
BackgroundGraefe‐Mody, U., Rose, P. W., Ring, A., Zander, K., Iovino, M., & Woerle, H. (2010) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.dmpk-10-rg-091 · Cited by 35 · cited 1×
“Therefore, linagliptin co-administration is not associated with clinically relevant effects on the pharmacokinetics or pharmacodynamics of other drugs commonly prescribed to patients with T2DM, such as metformin [12], pioglitazone [13], glyburide [14], simvastatin [15], warfarin [16], digoxin [17] or oral contraceptiv…”
BackgroundSelf-citationGraefe-Mody, E. U., Jungnik, A., Ring, A., et al. (2010) · International Journal of Clinical Pharmacology and Therapeutics · doi:10.5414/cpp48652 · Cited by 28 · cited 1×
“Therefore, linagliptin co-administration is not associated with clinically relevant effects on the pharmacokinetics or pharmacodynamics of other drugs commonly prescribed to patients with T2DM, such as metformin [12], pioglitazone [13], glyburide [14], simvastatin [15], warfarin [16], digoxin [17] or oral contraceptiv…”
BackgroundFriedrich, C., Port, A., Ring, A., Graefe‐Mody, U., Gießmann, T., Iovino, M., & Woerle, H. (2011) · Clinical Drug Investigation · doi:10.2165/11590240-000000000-00000 · Cited by 26 · cited 1×
“Therefore, linagliptin co-administration is not associated with clinically relevant effects on the pharmacokinetics or pharmacodynamics of other drugs commonly prescribed to patients with T2DM, such as metformin [12], pioglitazone [13], glyburide [14], simvastatin [15], warfarin [16], digoxin [17] or oral contraceptiv…”
BackgroundSelf-citationde Valk, H. W. (2007) · The Review of Diabetic Studies · doi:10.1900/rds.2007.4.126 · Cited by 14 · cited 1×
“com with complementary mechanisms of action to produce an additive or synergistic improvement in glycaemic control while minimizing the incidence of unwanted side effects [4].”
Background
Cited by
Dipeptidyl peptidase‐4 inhibitors in the treatment of type 2 diabetes: a comparative review
Deacon, C. F. (2011) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01306.x · Cited by 525
Kim, Y. G., Hahn, S., Oh, T. J., Kwak, S. H., Park, K. S., & Cho, Y. M. (2013) · Diabetologia · doi:10.1007/s00125-012-2827-3 · Cited by 396
Efficacy of GLP-1 Receptor Agonists and DPP-4 Inhibitors: Meta-Analysis and Systematic Review
Aroda, V. R., Henry, R. R., Han, J., Huang, W., DeYoung, M. B., Darsow, T., & Hoogwerf, B. J. (2012) · Clinical Therapeutics · doi:10.1016/j.clinthera.2012.04.013 · Cited by 251
Johansen, O., Neubacher, D., von Eynatten, M., Patel, S., & Woerle, H.-J. (2012) · Cardiovascular Diabetology · doi:10.1186/1475-2840-11-3 · Cited by 220
Self-citationBarnett, A. H., Huisman, H., Jones, R., von Eynatten, M., Patel, S., & Woerle, H.-J. (2013) · The Lancet · doi:10.1016/s0140-6736(13)61500-7 · Cited by 183
Self-citation
Metadata
- Authors
- Gomis, R., Espadero, R. ‐., Jones, R., Woerle, H. J., & Dugi, K. A.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2011-05-24
- Volume
- 13
- Issue
- 7
- Pages
- 653-661
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W2128648250
- Cited by
- 177
- References
- 20
- FWCI
- 25.18
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.